Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Launched by VANDA PHARMACEUTICALS · Nov 13, 2023

Keywords

ClinConnect Summary

The Motion Delos clinical trial is studying a new treatment called tradipitant for people who experience motion sickness during travel. Motion sickness can cause nausea, dizziness, and discomfort when you’re in a moving vehicle, like a car or airplane. This study aims to determine how safe and effective tradipitant is for adults between the ages of 18 and 75 who have a history of motion sickness.

If you or someone you know suffers from motion sickness and fits the age criteria, you might be eligible to participate. However, individuals with certain conditions, such as severe obesity or other nausea-related disorders, will not be able to join. Participants will receive the treatment and be monitored for any side effects and improvements in their symptoms. The trial is currently looking for volunteers, and it’s a great opportunity for those seeking relief from motion sickness during travel.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • History of Motion Sickness
• • Age 18-75
• Exclusion Criteria:
• • Nausea-inducing disorder other than motion sickness
• • BMI \> 40
• • History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists